Набира участници
Фаза 1
2025-522243-17-00
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.
Фаза 1 – тестване на безопасността при малка група хора
Заболявания:
Advanced solid tumors
specifically:
• metastatic clear cell renal carcinoma
• proficient mismatch repair / microsatellite stable (pMMR/MSS)
BRAF-V600E-mutant negative colorectal carcinoma
• locally advanced or metastatic pancreatic adenocarcinoma
Спонсор: Philogen S.p.A.
Налично на:
БГ
EN